2
项与 人脐带间充质干细胞 (汉密顿生物) 相关的临床试验Single Center, Open-label, Dose-increasing Phase I Clinical Trial of UC-MSCs for the Treatment of Knee Osteoarthritis
In recent years, the incidence rate and disability rate of osteoarthritis have continued to grow, and it has become a common chronic disease of elderly patients, second only to the "three highs", and poses a continuous threat to China's medical and health system and public health system. Knee osteoarthritis is the main type of osteoarthritis, ranking 11th in global disability diseases and 38th in disability adjusted life year loss, causing significant economic burden to patients, families, and society. At present, most of the treatment methods for KOA have limited efficacy, only relieving pain symptoms and cannot prevent cartilage damage and other tissue damage in the joints. Due to the limitations of adverse events, there is still no optimal treatment plan for KOA. Most studies believe that autologous mesenchymal stem cell transplantation is a new treatment method with good efficacy and good repair effect for mild to moderate cartilage defects. Given that there is currently no optimal treatment plan for KOA, human umbilical cord mesenchymal stem cell injection has potential development value and is of great significance for the treatment of KOA patients.
人脐带间充质干细胞注射液治疗膝关节骨性关节炎的单中心、开放、剂量递增 I 期临床试验
主要目的:评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的安全性和耐受性,为 II 期临床试验推荐合适的细胞治疗剂量(RP2D)。次要目的:评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的初步有效性。评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的免疫原性。
100 项与 人脐带间充质干细胞 (汉密顿生物) 相关的临床结果
100 项与 人脐带间充质干细胞 (汉密顿生物) 相关的转化医学
100 项与 人脐带间充质干细胞 (汉密顿生物) 相关的专利(医药)
100 项与 人脐带间充质干细胞 (汉密顿生物) 相关的药物交易